Plasma metabolomics in patients with atopic dermatitis following a single administration of Nemolizumab

Plasma metabolomics in patients with atopic dermatitis following a single administration of Nemolizumab - Plasma metabolomics in patients with atopic dermatitis following a single administration of Nemolizumab

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-jRCT1050240115

Enrollment

Registered

2024-08-26

Start date

2024-08-26

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Atopic dermatitis

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) Group with AD patients Stored plasma samples collected from AD patients with moderate or severe pruritus in the clinical trial (jRCT2080225290) will be used. 2)Group with healthy volunteers Stored plasma samples collected from healthy volunteers who have never been diagnosed with AD in the past and are not currently diagnosed with AD in the clinical research (jRCT1030230474) will be used.

Exclusion criteria

Exclusion criteria: 1) Group with AD patients Stored plasma samples collected from AD patients with moderate or severe pruritus in the clinical trial (jRCT2080225290) will be used. 2)Group with healthy volunteers Stored plasma samples collected from healthy volunteers who have never been diagnosed with AD in the past and are not currently diagnosed with AD in the clinical research (jRCT1030230474) will be used.

Design outcomes

Primary

Measure	Time frame
This study will perform explorative analysis of the temporal variations of each metabolite, using the pre-administration measurements of healthy adults and AD patients as controls. Based on these temporal variations, we will cluster the AD patients and perform metabolites pathway enrichment analysis for each cluster.	—

Contacts

Public ContactSusumu Hashimoto

Maruho Co.,Ltd. Kyoto R&D Center

hashimoto_dcl@mii.maruho.co.jp+81-75-325-3255

Outcome results